NASDAQ · XRTX
XORTX Therapeutics financials
$1.70−0.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Diluted shares | 4.7M | 2.9M | 2.0M | 1.5M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $864.5K | $2.5M | $3.4M | $10.4M | $14.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.7M | $4.1M | $5.5M | $12.4M | $17.4M |
| Total liabilities | $599.1K | $758.0K | $825.9K | $5.4M | $4.2M |
| Shareholders' equity | $2.1M | $3.3M | $4.6M | $7.0M | $13.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology